Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
charles balentine
pblabs.com

Bookmark and Share
Pinnacle BioLabs announces USPTO Patent to aid in Colorectal Cancer Screening
Pinnacle BioLabs announced US patent 61-947001, a new mass screening protocol for Colorectal Cancer Detection. Quantum RRS4 allows for patients to electronically return results, increasing compliance by an estimated 35%

BriefingWire.com, 3/05/2014 - Pinnacle BioLabs announced US patent 61-947001, a new mass screening protocol for Colorectal Cancer Detection. Quantum RRS4 allows for patients to electronically return results of the Pinnacle BioLabs Second Generation FIT Colorectal Cancer Detection test (FIT), increasing compliance by an estimated 35%. Pinnacle timed its announcement of the patent to coincide with Colorectal Cancer Awareness Month.

Quantum RRS4 (Remote Read Store and Forward) allows patients to perform the test in the comfort of their own home and digitally, using a smartphone or tablet, email or utilize a proprietary application to return results of their Colorectal Cancer test. The test promises to make the cumbersome, older automated FIT tests obsolete. Laboratories and HMO's no longer have to buy bulky equipment or reagents, nor spend the soft costs of having these tests resulted by their own personal. The Quantum RRS4 protocol intuitively aggregates tests results and reports them in a concise manner. Additionally, labs and organizations no longer have to spend hundreds of thousands of dollars on prepaid postage annually to get the results back.

Quantum RRS4 promises to revolutionize colorectal cancer screening, allowing for screening large populations at a fraction of the cost of the older automated tests.

Colon and Rectal Cancer is the Number cancer killer in the United States today, with an estimated 150,000 new cases annually, and 50,000 deaths annually. The averages persons chance of being diagnosed with colon cancer in their lifetime is 1 in 20.

Pinnacle BioLabs is pleased to offer the only at-home FIT Colorectal Cancer Detection Test. Lately there has been a lot of press regarding the FIT test - so what exactly is it? FIT stands for Fecal Immunochemical Test. A FIT test looks for occult (hidden) blood in the lower GI tract. Blood in the lower GI tract can be indicative of many things, such as Colon or Rectal Cancer, diverticulitis, colitis, Chron’s Disease, IBD, and IBS just to name a few. A positive FIT test should always be reported to your PCP or GI doctor.

The American College of Gastroenterology recommends a FIT test ANNUAL for persons over 50 - with African and Native Americans beginning an annual test at 45.

Additionally, for persons unwilling or unable to have a colonoscopy, the FIT test has been shown to be nearly as effective as colonoscopy for detecting colorectal cancer. Please note that while a FIT test may detect colon cancer or other disease states mentioned above, ONLY a colonoscopy can confirm these disease states.

About the Pinnacle BioLabs Second Generation FIT

Clinical studies have shown that the Pinnacle BioLabs Second Generation FIT Colorectal Cancer Detection test is highly sensitive for detecting blood in and around the stool, a key indicator of abnormalities in the colon and rectum that doctors use to help screen for colorectal cancer.

The test has an 87% sensitivity (sensitivity is defined as detecting a disease state when a disease state is in fact present) for colorectal cancer.In a study of patients who were at average risk, high risk or had no symptoms at all, The Pinnacle BioLabs Second Generation FIT was found to have 33% greater sensitivity for colorectal cancer than a leading guaiac-based FOBT screening test.

For more information on Pinnacle BioLabs, Quantum RRS4 technology, or FIT testing, visit PBLabs.com

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2025 Proserve Technology, Inc.